Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study.

Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):82-92.

PMID:
11176272
2.

Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study.

Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, Godfrey R, Jacobson LP.

AIDS. 2004 Mar 5;18(4):683-8.

PMID:
15090774
3.

Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the her study.

Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, Smith DK; HERS STUDY.

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):124-31.

PMID:
11588505
4.

Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.

Glass TR, De Geest S, Hirschel B, Battegay M, Furrer H, Covassini M, Vernazza PL, Bernasconi E, Rickenboch M, Weber R, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(1):77-85.

PMID:
18389901
5.

Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.

Ickovics JR, Cameron A, Zackin R, Bassett R, Chesney M, Johnson VA, Kuritzkes DR; Adult AIDS Clinical Trials Group 370 Protocol Team.

Antivir Ther. 2002 Sep;7(3):185-93.

PMID:
12487386
7.

Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up.

Nilsson Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G.

AIDS Care. 2006 May;18(4):407-14.

PMID:
16809121
8.

Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.

Eldred LJ, Wu AW, Chaisson RE, Moore RD.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jun 1;18(2):117-25.

PMID:
9637576
9.
10.

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM; ATHENA Project.

Arch Intern Med. 2001 Sep 10;161(16):1962-8.

PMID:
11525698
11.

Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment.

Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, Ngeth C, Ferradini L, Delfraissy JF, Laureillard D.

Antivir Ther. 2008;13(5):697-703.

PMID:
18771053
12.

Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection.

Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, Farley J, Malee K; PACTG 219C Team.

Pediatrics. 2006 Dec;118(6):e1745-57. Epub 2006 Nov 13.

PMID:
17101712
13.

Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.

Duval X, Mentré F, Lamotte C, Chêne G, Spire B, Dellamonica P, Panhard X, Salmon D, Raffi F, Peytavin G, Leport C; APROCO Study Group.

Ther Drug Monit. 2005 Feb;27(1):63-70. Erratum in: Ther Drug Monit. 2005 Aug;27(4):table of contents.

PMID:
15665749
14.

Sociodemographic and psychological variables influencing adherence to antiretroviral therapy.

Gordillo V, del Amo J, Soriano V, González-Lahoz J.

AIDS. 1999 Sep 10;13(13):1763-9.

PMID:
10509579
15.

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A; AdICONA Study Group.

J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):445-9.

PMID:
11744832
16.

Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.

Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.

Antivir Ther. 2004 Jun;9(3):407-14.

PMID:
15259903
17.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
18.

Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels.

Ahdieh Grant L, Silverberg MJ, Palacio H, Minkoff H, Anastos K, Young MA, Nowicki M, Kovacs A, Cohen M, Muñoz A.

AIDS. 2001 Nov 9;15(16):2101-8.

PMID:
11684929
19.

Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome.

DeMasi RA, Graham NM, Tolson JM, Pham SV, Capuano GA, Fisher RL, Shaefer MS, Pakes GE, Sawyerr GA, Eron JJ Jr.

Adv Ther. 2001 Jul-Aug;18(4):163-73.

PMID:
11697019
20.

Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2-year follow-up.

Nilsson Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G.

AIDS Care. 2006 Apr;18(3):246-53. Erratum in: AIDS Care. 2006 May;18(4):406. Corrected and republished in: AIDS Care. 2006 May;18(4):407-14.

PMID:
16546786
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk